Applied DNA Sciences has priced a $6.5 million registered direct offering and concurrent private placement at $0.32 per share. The offering includes 20,312,500 shares of common stock or pre-funded warrants, along with Series C and Series D warrants to purchase additional shares.The transaction structure includes Series C warrants exercisable at $0.32 per share expiring in 5 years after stockholder approval, and Series D warrants at the same exercise price expiring in 18 months after approval. The Series D warrants contain provisions for alternative cashless exercise and price reset protection in the event of a reverse stock split.The company plans to use proceeds for developing Therapeutic DNA Production Services and general corporate purposes. Craig-Hallum is acting as exclusive placement agent, with the offering expected to close around October 31, 2024. Additionally, the company amended certain existing Series A warrants to include a $0.20 floor price for price protection provisions.

Applied DNA Sciences has priced a $6.5 million registered direct offering and concurrent private placement at $0.32 per share. The offering includes 20,312,500 shares of common stock or pre-funded warrants, along with Series C and Series D warrants to purchase additional shares.The transaction structure includes Series C warrants exercisable at $0.32 per share expiring in 5 years after stockholder approval, and Series D warrants at the same exercise price expiring in 18 months after approval. The Series D warrants contain provisions for alternative cashless exercise and price reset protection in the event of a reverse stock split.The company plans to use proceeds for developing Therapeutic DNA Production Services and general corporate purposes. Craig-Hallum is acting as exclusive placement agent, with the offering expected to close around October 31, 2024. Additionally, the company amended certain existing Series A warrants to include a $0.20 floor price for price protection provisions.